FRα
1 EU-approved indication of 1 drug needs a FRα result, in 1 tumour type, most of them in ovarian cancer.
Approved indications1
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Ovarian cancer1 | ||||
Elahere | FRα-positive | Monotherapy | 2L | High-grade serous only; After 1 to 3 prior systemic treatment regimens; Platinum-resistant |
FRα by tumour
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Mirvetuximab soravtansine (Elahere)
ELAHERE as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens (see section 4.2).